## **Product** Data Sheet

Inhibitors

 Cat. No.:
 HY-19483

 CAS No.:
 630119-43-6

 Molecular Formula:
  $C_{19}H_{23}N_3O_2$ 

Molecular Weight: 325.4

Target: Dopamine Receptor

Pathway: GPCR/G Protein; Neuronal Signaling

Storage: Please store the product under the recommended conditions in the Certificate of

Analysis.

## -0.N¢

## **BIOLOGICAL ACTIVITY**

Description	ABT-670 is a selective, oral bioavailable agonist of dopamine $D_4$ receptor, with EC <sub>50</sub> of 89 nM, 160 nM, and 93 nM for human $D_4$ , ferret $D_4$ , and rat $D_4$ , respectively.
IC <sub>50</sub> & Target	EC50: 89 nM (Human D <sub>4</sub> ), 160 nM (Ferret D <sub>4</sub> ), 93 nM (Rat D <sub>4</sub> ) $^{[1]}$
In Vitro	ABT-670 is a selective $D_4$ agonist, with EC <sub>50</sub> of 89 nM, 160 nM, and 93 nM for human $D_4$ , ferret $D_4$ , and rat $D_4$ , respectively <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	ABT-670 (0.1 µmol/kg) robustly induces a high (75%) incidence of erections in male rats. ABT-670 exhibits excellent oral bioavailability in rat, dog, and monkey (68%, 85%, and 91%, respectively) with comparable efficacy, safety, and tolerability [1].  MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## **REFERENCES**

[1]. Patel MV, et al. Discovery of 3-methyl-N-(1-oxy-3',4',5',6'-tetrahydro-2'H-[2,4'-bipyridine]-1'-ylmethyl)benzamide (ABT-670), an orally bioavailable dopamine D4 agonist for the treatment of erectile dysfunction. J Med Chem. 2006 Dec 14;49(25):7450-65.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA